Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics in clinical practice: considerations for testing.

Simon Constable1, Michael R Johnson, Munir Pirmohamed

  • 1Department of Pharmacology & Therapeutics, Ashton Street Medical School, University of Liverpool, Ashton Street, Liverpool, L69 3GE, UK. s.constable@liverpool.ac.uk

Expert Review of Molecular Diagnostics
|March 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dosage effect of copy number variation in epilepsy and ten regions of the human brain.

Scientific reports·2025
Same author

Genome-wide association meta-analyses of drug-resistant epilepsy.

EBioMedicine·2025
Same author

Plasma metabolomic signatures for copy number variants and COVID-19 risk loci in Northern Finland populations.

Scientific reports·2025
Same author

Seeding-competent early tau multimers are associated with cell type-specific transcriptional signatures.

Acta neuropathologica·2025
Same author

Cell state-dependent allelic effects and contextual Mendelian randomization analysis for human brain phenotypes.

Nature genetics·2025
Same author

Microglia regulate cortical remyelination via TNFR1-dependent phenotypic polarization.

Cell reports·2024
Same journal

Navigating PD-L1 testing in immuno-oncology: analytical robustness, clinical validation, and the role of the VENTANA SP263 assay.

Expert review of molecular diagnostics·2026
Same journal

Extracellular vesicles as diagnostic and prognostic biomarkers in non-small cell lung cancer.

Expert review of molecular diagnostics·2026
Same journal

Explainable epigenetic aging clocks: an overview of existing AI models and approaches.

Expert review of molecular diagnostics·2026
Same journal

Neuro-axonal injury biomarker serum neurofilament light chain is associated with osteoarthritis: a dual-cohort study from NHANES and UK Biobank.

Expert review of molecular diagnostics·2026
Same journal

Diagnostics and novel laboratory approaches to combat <i>Neisseria gonorrhoeae</i> antimicrobial resistance.

Expert review of molecular diagnostics·2026
Same journal

Fluid biomarkers in cerebral amyloid angiopathy: current limitations and future directions.

Expert review of molecular diagnostics·2026
See all related articles

Pharmacogenetic tests require rigorous evaluation for clinical integration. Validated analytical, clinical, and cost-effectiveness criteria are essential for successful healthcare adoption.

Area of Science:

  • Biomedical Sciences
  • Genetics
  • Clinical Pharmacology

Background:

  • Pharmacogenetics is rapidly advancing, leading to new diagnostic tests.
  • Integrating these tests into healthcare systems presents resource challenges.
  • Existing screening test evaluation frameworks may inform pharmacogenetic test assessment.

Purpose of the Study:

  • To outline the multifaceted criteria for evaluating pharmacogenetic tests.
  • To emphasize the need for robust evidence for clinical adoption.
  • To guide the scientific assessment of pharmacogenetic technologies.

Main Methods:

  • Review of existing frameworks for evaluating screening tests.
  • Discussion of essential criteria: analytical validity, clinical validity, clinical utility, and cost-effectiveness.

Related Experiment Videos

  • Emphasis on defining study goals for evidence generation.

    • Main Results:

    • Pharmacogenetic tests must demonstrate reproducibility and clinical utility.
    • Cost-effectiveness analysis is crucial for healthcare resource allocation.
    • Early definition of goals is vital for designing appropriate validation studies.

    Conclusions:

    • Pharmacogenetic tests need comprehensive scientific assessment before clinical implementation.
    • Evidence-based evaluation is necessary for successful integration into healthcare.
    • Careful planning ensures pharmacogenetic testing fulfills its clinical potential.